Susquehanna International Group, LLP Aprea Therapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Call Options

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held	SEC Form
Q3 2022 Nov 14, 2022	BUY	$0.71 - $13.6 $10,579 - $202,640	14,900 Added 11.49%	144,600 $94,000
Q2 2022 Aug 15, 2022	BUY	$0.62 - $1.94 $2,790 - $8,730	4,500 Added 3.59%	129,700 $96,000
Q1 2022 May 16, 2022	BUY	$1.59 - $3.16 $161,862 - $321,688	101,800 Added 435.04%	125,200 $233,000
Q4 2021 Feb 14, 2022	SELL	$2.87 - $5.58 $55,965 - $108,810	-19,500 Reduced 45.45%	23,400 $67,000
Q2 2021 Aug 11, 2021	BUY	$4.05 - $5.5 $88,290 - $119,900	21,800 Added 103.32%	42,900 $209,000
Q1 2021 May 17, 2021	BUY	$4.73 - $8.15 $99,803 - $171,965	21,100 New	21,100 $108,000

Others Institutions Holding APRE

# of Institutions

2

Shares Held

899

Call Options Held

0

Put Options Held

0

Nbc Securities, Inc. Birmingham, AL

899
Shares

$2,625
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

About Aprea Therapeutics, Inc.

Ticker APRE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...

More about APRE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.